One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Ripretinib and the Failure to Advance GI Stromal Tumor Therapy in the Age of Precision Medicine.
Schwartz, Gary K. MD 1,
doi : 10.1200/JCO.22.01406
A Process Framework for Ethically Deploying Artificial Intelligence in Oncology.
Hantel, Andrew MD 1,; Clancy, Dillon D. BA 1; Kehl, Kenneth L. MD, MPH 1; Marron, Jonathan M. MD, MPH 1; Van Allen, Eliezer M. MD 1; Abel, Gregory A. MD, MPH 1
doi : 10.1200/JCO.22.01113
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Yue, Dongsheng MD 1; Xu, Shidong MD 2; Wang, Qun MD 3; Li, Xiaofei MD 4; Shen, Yi MD 5; Zhao, Heng MD 6; Chen, Chun MD 7; Mao, Weimin MD 8; Liu, Wei MD 9; Liu, Junfeng MD 10; Zhang, Lanjun MD 11; Ma, Haitao MD 12; Li, Qiang MD 13; Yang, Yue MD 14; Liu, Yongyu MD 15; Chen, Haiquan MD 16; Zhang, Zhenfa MD 1; Zhang, Bin MD 1; Wang, Changli MD 1,
doi : 10.1200/JCO.22.00428
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.
Bauer, Sebastian MD 1,2,; Jones, Robin L. MD, MBBS 3,; Blay, Jean-Yves MD, PhD 4,; Gelderblom, Hans MD, PhD 5,; George, Suzanne MD 6,; Schoffski, Patrick MD 7,; von Mehren, Margaret MD 8,; Zalcberg, John R. MD, PhD 9,; Kang, Yoon-Koo MD, PhD 10,; Razak, Albiruni Abdul MRCP, MBBCh 11,; Trent, Jonathan MD, PhD 12,; Attia, Steven DO 13,; Le Cesne, Axel MD 14,; Su, Ying MD, PhD 15,; Meade, Julie MD 15,; Wang, Tao PhD 15,; Sherman, Matthew L. MD 15,; Ruiz-Soto, Rodrigo MD 15,; Heinrich, Michael C. MD 16,17,
doi : 10.1200/JCO.22.00294
Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib.
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Kindler, Hedy L. MD 1,; Hammel, Pascal MD, PhD 2; Reni, Michele MD 3; Van Cutsem, Eric MD, PhD 4; Macarulla, Teresa MD, PhD 5; Hall, Michael J. MD 6; Park, Joon Oh MD, PhD 7; Hochhauser, Daniel MD, PhD 8; Arnold, Dirk MD, PhD 9; Oh, Do-Youn MD, PhD 10; Reinacher-Schick, Anke MD, PhD 11; Tortora, Giampaolo MD, PhD 12; Algul, Hana MD, PhD, MPH 13; O'Reilly, Eileen M. MD 14; Bordia, Sonal MD 15; McGuinness, David MSc 16; Cui, Karen MD, PhD 17; Locker, Gershon Y. MD 17; Golan, Talia MD 18
doi : 10.1200/JCO.21.01604
The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo for patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall survival (OS) and other secondary end points.
Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
Moncrieff, Marc D. MD 1,; Lo, Serigne N. PhD 2; Scolyer, Richard A. MD 2,3,4,5,; Heaton, Martin J. MD 1; Nobes, Jenny P. MBBS, BMedSci 1; Snelling, Andrew P. MBBChir 1; Carr, Michael J. MD, MS 6; Nessim, Carolyn MD, MSc 7,; Wade, Ryckie MBBS, MClinEd 8; Peach, A. Howard MD 8,; Kisyova, Rumi MD 9; Mason, Jennifer MBChB 9; Wilson, Ewan D. MSc 9; Nolan, Grant MBBS 10; Pritchard Jones, Rowan MD 10,; Johansson, Iva MD, PhD 11,12; Olofsson Bagge, Roger MD, PhD 11,12,; Wright, Lucie J. MBChB 13; Patel, Nakul G. MBBS 13,; Sondak, Vernon K. MD 6,; Thompson, John F. PhD 2,5,; Zager, Jonathan S. MD 6,
doi : 10.1200/JCO.21.02488
Indications for offering adjuvant systemic therapy for patients with early-stage melanomas with low disease burden sentinel node (SN) micrometastases, namely, American Joint Committee on Cancer (AJCC; eighth edition) stage IIIA disease, are presently controversial.
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk, Bradley J. MD 1,; Parkinson, Christine MD 2; Lim, Myong Cheol MD, PhD 3; O'Malley, David M. MD 4; Oaknin, Ana MD, PhD 5; Wilson, Michelle K. MD 6; Coleman, Robert L. MD 7; Lorusso, Domenica MD, PhD 8; Bessette, Paul MD 9; Ghamande, Sharad MD 10; Christopoulou, Athina MD, PhD 11; Provencher, Diane MD 12; Prendergast, Emily MD 13; Demirkiran, Fuat MD 14; Mikheeva, Olga MD 15; Yeku, Oladapo MD, PhD 16; Chudecka-Glaz, Anita MD, PhD 17; Schenker, Michael MD, PhD 18; Littell, Ramey D. MD 19; Safra, Tamar MD 20; Chou, Hung-Hsueh MD 21,22; Morgan, Mark A. MD 23; Drochytek, Vit MD 24; Barlin, Joyce N. MD 25; Van Gorp, Toon MD 26; Ueland, Fred MD 27; Lindahl, Gabriel MD 28,29; Anderson, Charles MD 30; Collins, Dearbhaile C. MBBCh, MA, PhD 31; Moore, Kathleen MD 32; Marme, Frederik MD, PhD 33; Westin, Shannon N. MD, MPH 34; McNeish, Iain A. MD, PhD 35; Shih, Danny BA 36; Lin, Kevin K. PhD 37; Goble, Sandra MS 38; Hume, Stephanie PhD 39; Fujiwara, Keiichi MD, PhD 40; Kristeleit, Rebecca S. MD, PhD 41
doi : 10.1200/JCO.22.01003
ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without BRCA1 or BRCA2 (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. We report the results from the ATHENA-MONO comparison of rucaparib versus placebo.
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You, Benoit MD, PhD 1,2,; Purdy, Christopher MA 3; Copeland, Larry J. MD 4; Swisher, Elizabeth M. MD 5; Bookman, Michael A. MD 6; Fleming, Gini MD 7; Coleman, Robert MD 8; Randall, Leslie M. MD 9; Tewari, Krishnansu S. MD 10; Monk, Bradley J. MD 11; Mannel, Robert S. MD 12; Walker, Joan L. MD 12; Cappuccini, Fabio MD 10; Cohn, David MD 4; Muzaffar, Mahvish MD 13; Mutch, David MD 14; Wahner-Hendrickson, Andrea MD 15; Martin, Lainie MD 16,17; Colomban, Olivier MSc 1,2; Burger, Robert A. MD 16,17
doi : 10.1200/JCO.22.01207
In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker.
Long-Term Morbidity and Mortality in Children After In Utero Exposure to Maternal Cancer.
Greiber, Iben K. MD 1,2,; Viuff, Jakob H. MScPH 2; Storgaard, Lone PhD 1; Karlsen, Mona A. PhD 1; Lidegaard, Ojvind DMSc 1; Mikkelsen, Anders P. MD 1; Mellemkjaer, Lene PhD 2; Hjortshoj, Cristel S. PhD 3
doi : 10.1200/JCO.22.00599
In utero exposure to maternal cancer and cancer treatment might influence the child's short- and long-term health and development. The objective of the study was to investigate short- and long-term somatic and psychiatric outcomes in children exposed to maternal cancer in utero.
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Mishra, Asmita MD 1,; Tamari, Roni MD 2; DeZern, Amy E. MD 3; Byrne, Michael T. DO 4; Gooptu, Mahasweta MD 5; Chen, Yi-Bin MD 6; Deeg, H. Joachim MD 7; Sallman, David MD 8; Gallacher, Phillip BSc 9; Wennborg, Anders MD, PhD 9; Hickman, Denice K. BSN, RN 9; Attar, Eyal C. MD 9; Fernandez, Hugo F. MD 10
doi : 10.1200/JCO.22.00181
Outcomes are poor in TP53-mutant (mTP53) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), even after allogeneic hematopoietic stem-cell transplant (HCT).
Eprenetapopt in the Post-Transplant Setting: Mechanisms and Future Directions.
Maiti, Abhishek MBBS 1,; Daver, Naval G. MD 1,
doi : 10.1200/JCO.22.01505
Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline.
Mao, Jun J. MD, MSCE 1,; Ismaila, Nofisat MD, MSc 2,; Bao, Ting MD 1,; Barton, Debra PhD 3; Ben-Arye, Eran MD 4; Garland, Eric L. PhD 5,; Greenlee, Heather ND, PhD 6; Leblanc, Thomas MD 7,; Lee, Richard T. MD 8,; Lopez, Ana Maria MD 9,; Loprinzi, Charles MD 10,; Lyman, Gary H. MD, MPH 6,; MacLeod, Jodi BA 11; Master, Viraj A. MD, PhD 12,; Ramchandran, Kavitha MD 13,; Wagner, Lynne I. PhD 14,; Walker, Eleanor M. MD 15; Bruner, Deborah Watkins PhD 12,; Witt, Claudia M. MD, MBA 16,; Bruera, Eduardo MD 17,,
doi : 10.1200/JCO.22.01357
The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other health care providers on integrative approaches to managing pain in patients with cancer.
A War Within the War.
Torniai, Mariangela MD 1,; Gucciardino, Calogero MD 1; Esperide, Barbara PsyD 1; Del Prete, Michela MD 1; Lanese, Andrea MD 1; Bisonni, Renato MD 1
doi : 10.1200/JCO.22.00745
Erratum: Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
doi : 10.1200/JCO.22.02228
Could the STELLAR Study Change the Rectal Cancer Treatment Algorithm?.
Sutcuoglu, Osman MD; Ozet, Ahmet MD; Yaz[latin dotless i]c[latin dotless i], Ozan MD; Ozdemir, Nuriye MD
doi : 10.1200/JCO.22.00752
Unconsolidated Results of Consolidation Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer.
Negri, Francesca MD, PhD; Aschele, Carlo MD, PhD
doi : 10.1200/JCO.22.00923
Chemoradiotherapy in Locally Advanced Rectal Cancer: Surgeon Perspective.
Yuksel, Bulent Cavit MD
doi : 10.1200/JCO.22.00934
Reply to O. Sutcuoglu et al, F. Negri et al, and B.C. Yuksel.
Tang, Yuan MD; Zhou, Hai-Tao MD; Li, Ye-Xiong MD; Jin, Jing MD
doi : 10.1200/JCO.22.01225
